PMID- 22994093
OWN - NLM
STAT- MEDLINE
DCOM- 20121031
LR  - 20191210
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 84
IP  - 8
DP  - 2012
TI  - [Evaluation of the efficiency and safety of therapy with a combination of 
      sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus].
PG  - 67-71
AB  - AIM: To evaluate the efficiency and safety of early combination therapy with 
      sulfonylurea derivatives (SUD) and insulin sensitizers in patients with type 2 
      diabetes mellitus (T2DM). SUBJECTS AND METHODS: Forty patients (31 women and 9 
      men; mean age 57.7 +/- 0.9 years) with decompensated T2DM (HbA(1c), 8.16 = +/- 
      0.27%), a mean body mass index of 32.7 +/- 0.27 kg/m2, who received glimepiride, 
      were examined. The duration of T2DM was 3.3 +/- 0.4 years. The patients had 
      concomitant cardiovascular diseases (CVD). Coronary heart disease and 
      hypertensive disease (HD) were treated; the doses of the agents were not adjusted 
      during the study. For T2DM compensation, all the patients were given insulin 
      sensitizers (rosiglitazone 4 mg) in addition to glimepiride. The treatment lasted 
      24 weeks. Carbohydrate and lipid metabolic parameters, insulin resistance, body 
      weight, structural and functional parameters, and heart rate were estimated 
      before and after the treatment. RESULTS: During the combination therapy, there 
      were decreases in the level of HbA(1c) from 8.16 +/- 0.27 to 6.84 +/- 0.15%, 
      fasting blood glucose from 8.89 +/- 0.35 to 6.77 +/- 0.16 mmol/l, postprandial 
      blood glucose from 8.66 +/- 0.24 to 7.761 +/- 0.20 mmol/l, HOMA index from 5.88 
      +/- 0.70 to 3.75 +/- 0.44. The rate of hypoglycemic reaction reduced. 
      Sugar-lowering therapy was observed to have, on average, a positive impact on 
      blood lipid composition and cardiovascular parameters in the group. 
      Echocardiography (EchoCG) identified a group of patients with negative cardiac 
      structural and functional changes. CONCLUSION: The combination therapy with SUD 
      and insulin sensitizers was stated to be effective in maintaining the reached 
      blood glucose level, reducing the risk of hypoglycemic reactions, and positively 
      affecting lipid metabolism. The therapy resulted in cardiovascular improvement 
      only in patients without obvious signs of CVD while it caused negative EchoCG 
      changes (transformation of concentric to eccentric left ventricular hypertrophy) 
      in patients with a long-term (more than 7 years) history of HD and pronounced 
      cardiac structural and functional alterations.
FAU - Goncharenko, O N
AU  - Goncharenko ON
FAU - Ametov, A S
AU  - Ametov AS
FAU - Isakova, M R
AU  - Isakova MR
LA  - rus
PT  - Evaluation Study
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 6KY687524K (glimepiride)
SB  - IM
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Rosiglitazone
MH  - Sulfonylurea Compounds/*administration & dosage/adverse effects
MH  - Thiazolidinediones/*administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2012/09/22 06:00
MHDA- 2012/11/01 06:00
CRDT- 2012/09/22 06:00
PHST- 2012/09/22 06:00 [entrez]
PHST- 2012/09/22 06:00 [pubmed]
PHST- 2012/11/01 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2012;84(8):67-71.